Paolo F Caimi1, Weiyun Ai2, Juan Pablo Alderuccio3, Kirit M Ardeshna4, Mehdi Hamadani5, Brian Hess6, Brad S Kahl7, John Radford8, Melhem Solh9, Anastasios Stathis10, Pier Luigi Zinzani11, Karin Havenith12, Jay Feingold13, Shui He13, Yajuan Qin13, David Ungar13, Xiaoyan Zhang13, Carmelo Carlo-Stella14. 1. University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA. Electronic address: paolo.caimi@case.edu. 2. Division of Haematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. 3. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. 4. Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK. 5. Blood and Marrow Transplant and Cellular Therapy Programme, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 6. Division of Haematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA. 7. Department of Medicine, Oncology Division, Washington University, St Louis, MO, USA. 8. National Institute for Health Research Manchester Clinical Research Facility, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. 9. Blood and Marrow Transplant Programme, Northside Hospital, Atlanta, GA, USA. 10. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. 11. IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli" and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy. 12. ADC Therapeutics UK, London, UK. 13. ADC Therapeutics America, Murray Hill, NJ, USA. 14. Department of Oncology and Haematology, Humanitas Clinical and Research Center, IRCCS, Humanitas University, Milan, Italy.
Abstract
BACKGROUND: Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who do not respond to or who have progressive disease after salvage therapies have a poor prognosis. Loncastuximab tesirine is a CD19-directed antibody-drug conjugate with encouraging phase 1 single-agent antitumour activity and acceptable safety in non-Hodgkin lymphoma. We aimed to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL. METHODS: We did a multicentre (28 hospital sites in the USA, UK, Italy, and Switzerland), open-label, single-arm, phase 2 trial (LOTIS-2) in patients aged 18 years or older with relapsed or refractory DLBCL after two or more multiagent systemic treatments, who had measurable disease and Eastern Cooperative Oncology Group performance status 0-2. Eligible patients received loncastuximab tesirine intravenously on day 1 of each 21-day cycle, at 150 μg/kg for two cycles, then 75 μg/kg thereafter, for up to 1 year or until disease relapse or progression, unacceptable toxicity, death, major protocol deviation, pregnancy, or patient, investigator, or sponsor decision. The primary endpoint was overall response rate assessed by central review. Primary antitumour activity and safety analyses were done in the as-treated population (patients who received at least one dose of loncastuximab tesirine), when all responding patients had at least 6 months of follow-up after initial documented response. Enrolment is complete. This trial is registered with ClinicalTrials.gov, NCT03589469. FINDINGS: Between Aug 1, 2018, and Sept 24, 2019, 184 patients were assessed for eligibility and 145 (79%) were enrolled and received at least one dose of loncastuximab tesirine, including patients with high-risk characteristics for poor prognosis, such as double-hit, triple-hit, transformed, or primary refractory DLBCL. 70 of 145 patients had complete or partial response (overall response rate 48·3% [95% CI 39·9-56·7]); 35 had complete response and 35 had partial response. The most common grade 3 or higher treatment-emergent adverse events were neutropenia (37 [26%] of 145 patients), thrombocytopenia (26 [18%]), and increased gamma-glutamyltransferase (24 [17%]). Serious adverse events were reported in 57 (39%) of 145 patients. Treatment-emergent adverse events with a fatal outcome occurred in eight (6%) of 145 patients; none were considered related to loncastuximab tesirine. INTERPRETATION: Loncastuximab tesirine has substantial single-agent antitumour activity and produces durable responses with an acceptable safety profile, potentially offering a new therapeutic option for heavily pretreated patients with relapsed or refractory DLBCL. FUNDING: ADC Therapeutics.
BACKGROUND:Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who do not respond to or who have progressive disease after salvage therapies have a poor prognosis. Loncastuximab tesirine is a CD19-directed antibody-drug conjugate with encouraging phase 1 single-agent antitumour activity and acceptable safety in non-Hodgkin lymphoma. We aimed to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL. METHODS: We did a multicentre (28 hospital sites in the USA, UK, Italy, and Switzerland), open-label, single-arm, phase 2 trial (LOTIS-2) in patients aged 18 years or older with relapsed or refractory DLBCL after two or more multiagent systemic treatments, who had measurable disease and Eastern Cooperative Oncology Group performance status 0-2. Eligible patients received loncastuximab tesirine intravenously on day 1 of each 21-day cycle, at 150 μg/kg for two cycles, then 75 μg/kg thereafter, for up to 1 year or until disease relapse or progression, unacceptable toxicity, death, major protocol deviation, pregnancy, or patient, investigator, or sponsor decision. The primary endpoint was overall response rate assessed by central review. Primary antitumour activity and safety analyses were done in the as-treated population (patients who received at least one dose of loncastuximab tesirine), when all responding patients had at least 6 months of follow-up after initial documented response. Enrolment is complete. This trial is registered with ClinicalTrials.gov, NCT03589469. FINDINGS: Between Aug 1, 2018, and Sept 24, 2019, 184 patients were assessed for eligibility and 145 (79%) were enrolled and received at least one dose of loncastuximab tesirine, including patients with high-risk characteristics for poor prognosis, such as double-hit, triple-hit, transformed, or primary refractory DLBCL. 70 of 145 patients had complete or partial response (overall response rate 48·3% [95% CI 39·9-56·7]); 35 had complete response and 35 had partial response. The most common grade 3 or higher treatment-emergent adverse events were neutropenia (37 [26%] of 145 patients), thrombocytopenia (26 [18%]), and increased gamma-glutamyltransferase (24 [17%]). Serious adverse events were reported in 57 (39%) of 145 patients. Treatment-emergent adverse events with a fatal outcome occurred in eight (6%) of 145 patients; none were considered related to loncastuximab tesirine. INTERPRETATION:Loncastuximab tesirine has substantial single-agent antitumour activity and produces durable responses with an acceptable safety profile, potentially offering a new therapeutic option for heavily pretreated patients with relapsed or refractory DLBCL. FUNDING: ADC Therapeutics.
Authors: Brian Hess; William Townsend; Weiyun Ai; Anastasios Stathis; Melhem Solh; Juan Pablo Alderuccio; David Ungar; Sam Liao; Lori Liao; Lisa Khouri; Xiaoyan Zhang; Joseph Boni Journal: AAPS J Date: 2021-12-10 Impact factor: 4.009
Authors: Ana Carolina Caballero; Laura Escribà-Garcia; Carmen Alvarez-Fernández; Javier Briones Journal: Front Immunol Date: 2022-07-06 Impact factor: 8.786
Authors: Alexis Eras; Danna Castillo; Margarita Suárez; Nelson Santiago Vispo; Fernando Albericio; Hortensia Rodriguez Journal: Front Chem Date: 2022-05-26 Impact factor: 5.545
Authors: Ajlan Al Zaki; Lei Feng; Grace Watson; Sairah A Ahmed; Haleigh Mistry; Loretta J Nastoupil; Misha Hawkins; Ranjit Nair; Swaminathan P Iyer; Hun J Lee; Raphael E Steiner; Christopher R Flowers; Elizabeth J Shpall; Partow Kebriaei; Sattva S Neelapu; Jason R Westin; Paolo Strati Journal: Blood Adv Date: 2022-05-10
Authors: Yvette L Kasamon; Lauren S L Price; Olanrewaju O Okusanya; Nicholas C Richardson; Ruo-Jing Li; Lian Ma; Yu-Te Wu; Marc Theoret; Richard Pazdur; Nicole J Gormley Journal: Oncologist Date: 2021-07-01